These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Acute and chronic effects of UDCG 115 BS (pimobendan) in patients with advanced myocardial failure].
    Author: Permanetter B, Baumann G, Wirtzfeld A, Günes S, Stinshoff M, Klein G.
    Journal: Z Kardiol; 1989 May; 78(5):335-42. PubMed ID: 2660451.
    Abstract:
    In a double-blind, placebo-controlled cross-over study acute hemodynamic effects of oral UDCG 115 BS (5 and 10 mg) were investigated in myocardial heart failure before (n = 16) and after (n = 13) chronic treatment (4 weeks). Before chronic treatment, UDCG 115 BS induced a similar increase in cardiac index with both doses (5 mg: from 2.4 +/- 0.7 to 3.5 +/- 0.7 l/min/m2, p less than 0.001; 10 mg: from 2.5 +/- 0.6 to 3.6 +/- 0.9 l/min/m2, p less than 0.001). Both right atrial pressure and pulmonary capillary wedge pressure were clearly reduced (p less than 0.001). Heart rate increased slightly only after 5 mg (p less than 0.05). Systemic vascular resistance was reduced (p less than 0.001), whereas mean blood pressure did not change. After chronic treatment (2 x 5 or 2 x 10 mg/d) and cessation of medication for 24 h there was no difference for control hemodynamic values as compared to placebo. Acute hemodynamic effects were considerably attenuated in comparison with the results obtained before chronic treatment. NYHA-classification, however, clearly (p less than 0.05) improved during administration of UDCG 115 BS as compared to placebo. Two patients died on placebo, whereas no patient expired on verum. This might indicate a therapeutic longterm effect of UDCG 115 BS, despite the observed development of partial tolerance.
    [Abstract] [Full Text] [Related] [New Search]